Transforming growth factor-beta (TGF-beta) mediates cell cycle arrest by activating cdk inhibitors, principle among which is p27[Kip1]. Loss of growth inhibition by TGF-beta occurs early in oncogenesis and contributes to tumor progression. We have studied cell cycle effects of TGF-beta and how they are lost in human tumors, p27 is often inactivated in human cancers due to accelerated p27 proteolysis or cytoplasmic mislocalization of p27. In cancer cells, progressive checkpoint loss makes p27 essential for TGF-beta mediated arrest. We showed activation of the phosphoinositol 3' kinase (PI3K) effector, protein kinase B (PKB) phosphorylates p27 at threonine 157, mislocalizating p27 in the cytoplasm. PKB activated cells also showed increased p27 in cyclin D1-cdk complexes. Preliminary data suggest that other effectors of the PI3K pathway may also inhibit p27 function. PI3K and its downstream effector pathways are often activated in cancers by oncogenic receptor tyrosine kinase overexpression, activating ras mutations or loss of the PI3K inhibitor, PTEN. Here we investigate how p27 function and G1 arrest by TGF-beta may be opposed by mitogenic PI3K signaling in cancers. Our hypothesis is that constitutive activation of the PI3K pathway leads to p27 phosphorylation events that reduce its affinity for cyclin E-cdk2, alter its stability and intraceltular localization, and abrogate its inhibitory function leading to TGF-beta resistance. This is pursued by the following specific aims:
AIM 1) to assay if PKB activates p27 assembly function toward cyclin D1-cdk4 and reduces p27's inhibitory action toward cyclin E-cdk2;
AIM 2) to determine whether PI3K effectors other than PKB can mediate TGF-beta resistance;
AIM 3) to assay if other PI3K dependent kinases can phosphorylate p27 and alter its function and AIM 4) to investigate whether PI3K effectors impair nuclear import of p27. These studies may link TGF-beta resistance to oncogenic activation of mitogenic P13K signaling pathways commonly observed in human cancers. Elucidation of molecular mechanisms of p27 inactivation and TGF-beta resistance in cancers may yield new targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA105118-04
Application #
7186636
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Blair, Donald G
Project Start
2004-03-23
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2009-02-28
Support Year
4
Fiscal Year
2007
Total Cost
$235,586
Indirect Cost
Name
University of Miami School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Zhao, D; Besser, A H; Wander, S A et al. (2015) Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene 34:5447-59
Wander, Seth A; Zhao, Dekuang; Besser, Alexandra H et al. (2013) PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat 138:369-81
Wander, Seth A; Hennessy, Bryan T; Slingerland, Joyce M (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121:1231-41
Wander, Seth A; Zhao, Dekuang; Slingerland, Joyce M (2011) p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 17:12-8
Larrea, Michelle D; Wander, Seth A; Slingerland, Joyce M (2009) p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 8:3455-61
Larrea, Michelle D; Hong, Feng; Wander, Seth A et al. (2009) RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A 106:9268-73
Larrea, Michelle D; Liang, Jiyong; Da Silva, Thiago et al. (2008) Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 28:6462-72
Hong, Feng; Larrea, Michelle D; Doughty, Cheryl et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30:701-11
Chu, Isabel M; Hengst, Ludger; Slingerland, Joyce M (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253-67
Chu, Isabel; Sun, Jun; Arnaout, Angel et al. (2007) p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128:281-94